^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Alymsys (bevacizumab-maly)

i
Other names: BEVZ92, MB02
Company:
Amneal, Insud Pharma, Nichi-Iko, Pharmaceutical Libbs, Stada
Drug class:
VEGF-A inhibitor
Related drugs:
3ms
A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®. (clinicaltrials.gov)
P1, N=114, Completed, mAbxience Research S.L. | Active, not recruiting --> Completed
Trial completion
|
Alymsys (bevacizumab-maly)
over1year
In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma. (PubMed, Animals (Basel))
Additionally, canine VEGF-induced microvascular endothelial cell proliferation was inhibited in a concentration-dependent manner by MB02 biosimilar. These encouraging results show a high potential for MB02 as a promising therapeutic agent for the management of CMC.
Preclinical • Journal
|
Alymsys (bevacizumab-maly)